Where does OCRA's clinical trial data come from?

OCRA indexes clinical trials from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Trials are matched to diseases, investigators, and funded research tracked across the platform.

How do I find clinical trials for ovarian cancer?

Search by condition, treatment type, trial phase, or NCT identifier. Each trial page shows current status, eligibility criteria, study locations, and a direct link to the ClinicalTrials.gov source record.

How often is clinical trial data updated?

Trial data is refreshed through periodic ingestion from the ClinicalTrials.gov v2 API. Status changes, new enrollments, and newly registered trials are captured during each update cycle.

Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide

NCT00188695CompletedPHASE1, PHASE2INTERVENTIONAL

Summary

The purpose of this study is to test whether or not a new contrast agent called Combidex, a contrast agent formulated from ultra-small superparamagnetic iron oxide (USPIO) improves the ability of Magnetic Resonance Imaging (MRI) to see lymph nodes in the pelvis. It might also help doctors tell whether or not cancer has spread to these lymph nodes. It might allow radiotherapy to be delivered more accurately.

Key Facts

Lead Sponsor

University Health Network, Toronto

Enrollment

Start Date

2004-04-01

Completion Date

2006-06-01

Study Type

INTERVENTIONAL

Official Title

A Pilot Study of MR Imaging With Ultra-small Superparamagnetic Iron Oxide for Pelvic Lymph Node Target Definition

Interventions

MRI contrast agent Combidex (ferumoxtran-10)

Conditions

Uterine NeoplasmsCervix NeoplasmsBladder NeoplasmsProstatic Neoplasms

Eligibility

Age Range

18 Years+

Sex

ALL

Inclusion Criteria:

* histologically confirmed endometrial, cervix, prostate (cT1-cT3) or bladder cancer
* no distant metastases
* informed consent

Exclusion Criteria:

* confirmed prostate carcinoma and PSA less than or equal to 4 or greater than 100
* radical surgery or prior cryosurgery for prostate carcinoma, previous RT, hormonal manipulation or chemotherapy
* biopsy-proven lymph node involvement
* endometrium or cervix carcinoma who have undergone recent pelvic surgery with the exclusion of D\&C or biopsy
* bladder carcinoma with recent pelvic surgery with the exclusion of TURBT
* previous or concurrent cancers other than superficial basal or squamous cell skin carcinoma unless disease-free for at least 5 yrs
* contraindication to MR imaging
* hip prosthesis
* major medical or psychiatric illness
* patients with known allergy to dextran or iron-containing compounds
* patients with cirrhosis or hemochromatosis
* patients receiving another MR contrast within 2 hrs prior to the ferumoxtran-10

Outcome Measures

Primary Outcomes

Improved delineation of normal pelvic lymph nodes in patients with uterine, cervical, bladder and prostate cancers.

Time frame: once at time of imaging

Improved clinical target volume (CTV) definition for the purpose of adjuvant irradiation of pelvic lymph nodes using intensity modulated radiotherapy (IMRT).

Time frame: once at time of imaging

Secondary Outcomes

Comparison of target lymph node delineation between nodal imaging with USPIO and volume expansion of vascular anatomy.

Time frame: once at time of imaging

Demonstration of the pattern and distribution of pelvic nodal metastases in patients with uterine, cervical, bladder and prostate cancers.

Time frame: once at time of imaging

Locations

Princess Margaret Hospital, Toronto, Canada